butorphanol + ropivacaine + sufentanil

butorphanol + ropivacaine + sufentanil is a combination analgesic regimen investigated for the management of postoperative pain, particularly following gynecological and obstetric procedures such as cesarean sections. This combination utilizes three distinct pharmacological agents to achieve synergistic pain relief: ropivacaine, a long-acting aminoamide local anesthetic that blocks voltage-gated sodium channels to inhibit nerve impulse conduction; sufentanil, a highly potent mu-opioid receptor agonist that provides profound central analgesia; and butorphanol, a mixed opioid agonist-antagonist that acts as an agonist at kappa-opioid receptors and a partial agonist/antagonist at mu-opioid receptors. The inclusion of butorphanol is often intended to enhance analgesia via the kappa pathway while potentially reducing mu-opioid-induced side effects like pruritus and nausea. This specific triple combination has been studied by researchers at the Obstetrics and Gynecology Hospital of Fudan University for use in patient-controlled epidural analgesia (PCEA) to improve recovery outcomes and patient satisfaction.